ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Thoughts on GHK-cu capsules?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="BadassBlues" data-source="post: 271598" data-attributes="member: 38526"><p>I can see a possible potential for an oral BPC-157 product to be used in conjunction with Semaglutide or Tirzepatide due to the positive effects on the digestive system. Here is an interesting study:</p><p></p><p>[URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/[/URL]</p><p></p><h3><em>Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications</em></h3><p><em><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sikiric%20P%5BAuthor%5D" target="_blank">Predrag Sikiric</a>,1,* <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Seiwerth%20S%5BAuthor%5D" target="_blank">Sven Seiwerth</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rucman%20R%5BAuthor%5D" target="_blank">Rudolf Rucman</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kolenc%20D%5BAuthor%5D" target="_blank">Danijela Kolenc</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Vuletic%20LB%5BAuthor%5D" target="_blank">Lovorka Batelja Vuletic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Drmic%20D%5BAuthor%5D" target="_blank">Domagoj Drmic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Grgic%20T%5BAuthor%5D" target="_blank">Tihomir Grgic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Strbe%20S%5BAuthor%5D" target="_blank">Sanja Strbe</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zukanovic%20G%5BAuthor%5D" target="_blank">Goran Zukanovic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Crvenkovic%20D%5BAuthor%5D" target="_blank">Dalibor Crvenkovic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Madzarac%20G%5BAuthor%5D" target="_blank">Goran Madzarac</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rukavina%20I%5BAuthor%5D" target="_blank">Iva Rukavina</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sucic%20M%5BAuthor%5D" target="_blank">Mario Sucic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Baric%20M%5BAuthor%5D" target="_blank">Marko Baric</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Starcevic%20N%5BAuthor%5D" target="_blank">Neven Starcevic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Krstonijevic%20Z%5BAuthor%5D" target="_blank">Zoran Krstonijevic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Bencic%20ML%5BAuthor%5D" target="_blank">Martina Lovric Bencic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Filipcic%20I%5BAuthor%5D" target="_blank">Igor Filipcic</a>,1 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rokotov%20DS%5BAuthor%5D" target="_blank">Dinko Stancic Rokotov</a>,1 and <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Vlainic%20J%5BAuthor%5D" target="_blank">Josipa Vlainic</a>2</em></p><p><em><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#" target="_blank">Author information</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#" target="_blank">Article notes</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#" target="_blank">Copyright and License information</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/about/disclaimer/" target="_blank">PMC Disclaimer</a></em></p><p><em></em></p><p><em><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#" target="_blank">Go to:</a></em></p><h3><em>Abstract</em></h3><h4><em>Background</em></h4><p><em>Brain-gut interaction involves, among others, peptidergic growth factors which are native in GI tract and have strong antiulcer potency and thus could from periphery beneficially affect CNS-disorders. We focused on the stable gastric pentadecapeptide BPC 157, an antiulcer peptidergic agent, safe in inflammatory bowel disease trials and now in multiple sclerosis trial, native and stable in human gastric juice.</em></p><h4><em>Methods</em></h4><p><em>Review of our research on BPC 157 in terms of brain-gut axis.</em></p><h4><em>Results</em></h4><p><em>BPC 157 may serve as a novel mediator of Robert’s cytoprotection, involved in maintaining of GI mucosa integrity, with no toxic effect. BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Stimulated Egr-1 gene, NAB2, FAK-paxillin and JAK-2 pathways are hitherto implicated. Initially corresponding beneficial central influence was seen when BPC 157 was given peripherally and a serotonin release in particular brain areas, mostly nigrostriatal, was changed. BPC 157 modulates serotonergic and dopaminergic systems, beneficially affects various behavioral disturbances that otherwise appeared due to specifically (over)stimulated/damaged neurotransmitters systems. Besides, BPC 157 has neuroprotective effects: protects somatosensory neurons; peripheral nerve regeneration appearent after transection; after traumatic brain injury counteracts the otherwise progressing course, in rat spinal cord compression with tail paralysis, axonal and neuronal necrosis, demyelination, cyst formation and rescues tail function in both short-terms and long-terms; after NSAIDs or insulin overdose or cuprizone encephalopathies were attenuated along with GI, liver and vascular injuries.</em></p><h4><em>Conclusion</em></h4><p><em>BPC 157, a gastric peptide, may serve as remedy in various CNS-disorders.</em></p></blockquote><p></p>
[QUOTE="BadassBlues, post: 271598, member: 38526"] I can see a possible potential for an oral BPC-157 product to be used in conjunction with Semaglutide or Tirzepatide due to the positive effects on the digestive system. Here is an interesting study: [URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/[/URL] [HEADING=2][I]Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications[/I][/HEADING] [I][URL='https://pubmed.ncbi.nlm.nih.gov/?term=Sikiric%20P%5BAuthor%5D']Predrag Sikiric[/URL],1,* [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Seiwerth%20S%5BAuthor%5D']Sven Seiwerth[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Rucman%20R%5BAuthor%5D']Rudolf Rucman[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Kolenc%20D%5BAuthor%5D']Danijela Kolenc[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Vuletic%20LB%5BAuthor%5D']Lovorka Batelja Vuletic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Drmic%20D%5BAuthor%5D']Domagoj Drmic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Grgic%20T%5BAuthor%5D']Tihomir Grgic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Strbe%20S%5BAuthor%5D']Sanja Strbe[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Zukanovic%20G%5BAuthor%5D']Goran Zukanovic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Crvenkovic%20D%5BAuthor%5D']Dalibor Crvenkovic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Madzarac%20G%5BAuthor%5D']Goran Madzarac[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Rukavina%20I%5BAuthor%5D']Iva Rukavina[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Sucic%20M%5BAuthor%5D']Mario Sucic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Baric%20M%5BAuthor%5D']Marko Baric[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Starcevic%20N%5BAuthor%5D']Neven Starcevic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Krstonijevic%20Z%5BAuthor%5D']Zoran Krstonijevic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Bencic%20ML%5BAuthor%5D']Martina Lovric Bencic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Filipcic%20I%5BAuthor%5D']Igor Filipcic[/URL],1 [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Rokotov%20DS%5BAuthor%5D']Dinko Stancic Rokotov[/URL],1 and [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Vlainic%20J%5BAuthor%5D']Josipa Vlainic[/URL]2 [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#']Author information[/URL] [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#']Article notes[/URL] [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#']Copyright and License information[/URL] [URL='https://www.ncbi.nlm.nih.gov/pmc/about/disclaimer/']PMC Disclaimer[/URL] [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#']Go to:[/URL][/I] [HEADING=2][I]Abstract[/I][/HEADING] [HEADING=3][I]Background[/I][/HEADING] [I]Brain-gut interaction involves, among others, peptidergic growth factors which are native in GI tract and have strong antiulcer potency and thus could from periphery beneficially affect CNS-disorders. We focused on the stable gastric pentadecapeptide BPC 157, an antiulcer peptidergic agent, safe in inflammatory bowel disease trials and now in multiple sclerosis trial, native and stable in human gastric juice.[/I] [HEADING=3][I]Methods[/I][/HEADING] [I]Review of our research on BPC 157 in terms of brain-gut axis.[/I] [HEADING=3][I]Results[/I][/HEADING] [I]BPC 157 may serve as a novel mediator of Robert’s cytoprotection, involved in maintaining of GI mucosa integrity, with no toxic effect. BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Stimulated Egr-1 gene, NAB2, FAK-paxillin and JAK-2 pathways are hitherto implicated. Initially corresponding beneficial central influence was seen when BPC 157 was given peripherally and a serotonin release in particular brain areas, mostly nigrostriatal, was changed. BPC 157 modulates serotonergic and dopaminergic systems, beneficially affects various behavioral disturbances that otherwise appeared due to specifically (over)stimulated/damaged neurotransmitters systems. Besides, BPC 157 has neuroprotective effects: protects somatosensory neurons; peripheral nerve regeneration appearent after transection; after traumatic brain injury counteracts the otherwise progressing course, in rat spinal cord compression with tail paralysis, axonal and neuronal necrosis, demyelination, cyst formation and rescues tail function in both short-terms and long-terms; after NSAIDs or insulin overdose or cuprizone encephalopathies were attenuated along with GI, liver and vascular injuries.[/I] [HEADING=3][I]Conclusion[/I][/HEADING] [I]BPC 157, a gastric peptide, may serve as remedy in various CNS-disorders.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Thoughts on GHK-cu capsules?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top